- Home
- BRIA vs CELU Comparison
BRIA vs CELU Comparison
Compare BRIA & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRIA
- CELU
- Stock Information
- Founded
- BRIA 2011
- CELU 2016
- Country
- BRIA Singapore
- CELU United States
- Employees
- BRIA N/A
- CELU N/A
- Industry
- BRIA
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- BRIA
- CELU Health Care
- Exchange
- BRIA NYSE
- CELU Nasdaq
- Market Cap
- BRIA 47.1M
- CELU 42.2M
- IPO Year
- BRIA 2024
- CELU N/A
- Fundamental
- Price
- BRIA $2.73
- CELU $1.67
- Analyst Decision
- BRIA
- CELU
- Analyst Count
- BRIA 0
- CELU 0
- Target Price
- BRIA N/A
- CELU N/A
- AVG Volume (30 Days)
- BRIA 29.1K
- CELU 36.7K
- Earning Date
- BRIA 05-23-2025
- CELU 12-06-2024
- Dividend Yield
- BRIA N/A
- CELU N/A
- EPS Growth
- BRIA N/A
- CELU N/A
- EPS
- BRIA 92.24
- CELU N/A
- Revenue
- BRIA $59,695,825.00
- CELU $54,220,000.00
- Revenue This Year
- BRIA N/A
- CELU N/A
- Revenue Next Year
- BRIA N/A
- CELU $233.89
- P/E Ratio
- BRIA $0.03
- CELU N/A
- Revenue Growth
- BRIA 8.03
- CELU 138.11
- 52 Week Low
- BRIA $1.78
- CELU $1.00
- 52 Week High
- BRIA $4.38
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- BRIA N/A
- CELU 53.51
- Support Level
- BRIA N/A
- CELU $1.53
- Resistance Level
- BRIA N/A
- CELU $1.68
- Average True Range (ATR)
- BRIA 0.00
- CELU 0.15
- MACD
- BRIA 0.00
- CELU 0.02
- Stochastic Oscillator
- BRIA 0.00
- CELU 54.55
About BRIA BRILLIA INC
BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.